These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 38698877)
41. Severe Cardiomyopathy as the Isolated Presenting Feature in an Adult with Late-Onset Pompe Disease: A Case Report. Mori M; Bailey LA; Estrada J; Rehder CW; Li JS; Rogers JG; Bali DS; Buckley AF; Kishnani PS JIMD Rep; 2017; 31():79-83. PubMed ID: 27142047 [TBL] [Abstract][Full Text] [Related]
42. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Yang CF; Liu HC; Hsu TR; Tsai FC; Chiang SF; Chiang CC; Ho HC; Lai CJ; Yang TF; Chuang SY; Lin CY; Niu DM Am J Med Genet A; 2014 Jan; 164A(1):54-61. PubMed ID: 24243590 [TBL] [Abstract][Full Text] [Related]
43. Diagnostic tools in late onset Pompe disease (LOPD). Musumeci O; Toscano A Ann Transl Med; 2019 Jul; 7(13):286. PubMed ID: 31392198 [TBL] [Abstract][Full Text] [Related]
44. Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease. Farah BL; Madden L; Li S; Nance S; Bird A; Bursac N; Yen PM; Young SP; Koeberl DD FASEB J; 2014 May; 28(5):2272-80. PubMed ID: 24448824 [TBL] [Abstract][Full Text] [Related]
45. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Feeney EJ; Austin S; Chien YH; Mandel H; Schoser B; Prater S; Hwu WL; Ralston E; Kishnani PS; Raben N Acta Neuropathol Commun; 2014 Jan; 2():2. PubMed ID: 24383498 [TBL] [Abstract][Full Text] [Related]
46. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS; Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424 [TBL] [Abstract][Full Text] [Related]
47. Suppression of mTORC1 activation in acid-α-glucosidase-deficient cells and mice is ameliorated by leucine supplementation. Shemesh A; Wang Y; Yang Y; Yang GS; Johnson DE; Backer JM; Pessin JE; Zong H Am J Physiol Regul Integr Comp Physiol; 2014 Nov; 307(10):R1251-9. PubMed ID: 25231351 [TBL] [Abstract][Full Text] [Related]
49. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. Han SO; Li S; Bird A; Koeberl D Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913 [TBL] [Abstract][Full Text] [Related]
50. Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives. El Haddad L; Khan M; Soufny R; Mummy D; Driehuys B; Mansour W; Kishnani PS; ElMallah MK Ther Clin Risk Manag; 2023; 19():713-729. PubMed ID: 37680303 [TBL] [Abstract][Full Text] [Related]
51. Neural deficits contribute to respiratory insufficiency in Pompe disease. DeRuisseau LR; Fuller DD; Qiu K; DeRuisseau KC; Donnelly WH; Mah C; Reier PJ; Byrne BJ Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9419-24. PubMed ID: 19474295 [TBL] [Abstract][Full Text] [Related]
52. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant. Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071 [TBL] [Abstract][Full Text] [Related]
53. Prevalence of adult Pompe disease in patients with proximal myopathic syndrome and undiagnosed muscle biopsy. Golsari A; Nasimzadah A; Thomalla G; Keller S; Gerloff C; Magnus T Neuromuscul Disord; 2018 Mar; 28(3):257-261. PubMed ID: 29326002 [TBL] [Abstract][Full Text] [Related]
54. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families. Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278 [TBL] [Abstract][Full Text] [Related]
55. Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe Disease. Liao HC; Chan MJ; Yang CF; Chiang CC; Niu DM; Huang CK; Gelb MH Clin Chem; 2017 Jul; 63(7):1271-1277. PubMed ID: 28450385 [TBL] [Abstract][Full Text] [Related]
56. Late-onset Pompe disease in a 54 year-old sportsman with an episode of syncope: a case report. Walczak-Galezewska M; Skrypnik D; Szulinska M; Musialik K; Skrypnik K; Bogdanski P Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3665-3667. PubMed ID: 28925476 [TBL] [Abstract][Full Text] [Related]
57. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258 [TBL] [Abstract][Full Text] [Related]
59. Pompe disease: early diagnosis and early treatment make a difference. Chien YH; Hwu WL; Lee NC Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029 [TBL] [Abstract][Full Text] [Related]
60. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase. Puzzo F; Colella P; Biferi MG; Bali D; Paulk NK; Vidal P; Collaud F; Simon-Sola M; Charles S; Hardet R; Leborgne C; Meliani A; Cohen-Tannoudji M; Astord S; Gjata B; Sellier P; van Wittenberghe L; Vignaud A; Boisgerault F; Barkats M; Laforet P; Kay MA; Koeberl DD; Ronzitti G; Mingozzi F Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187643 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]